foxo4-dri senolytic peptide human trials Selectively Removes Senescent Cells From in vitro Expanded Chondrocytes Peptide Inhibitors Targeting FOXO4-p53 Interactions
Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine (PDF) Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOX04 DRI (10mg) Nordsci
Pay in 4 interest-free payments of $6.59 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6




